According to Zhejiang Online on June 7th, Taiwan media such as United Daily reported on June 7th that the 62 year old "singing god" Jacky Cheung was originally scheduled to hold his fourth "60+" tour at Taipei Arena on the evening of the 7th. The organizers confirmed that he was feeling unwell and the concert was suspended.
Jacky Cheung also stated through the official social media account of Universal Music that he has been infected with RSV (respiratory syncytial virus) and is unable to speak normally, confirming that he cannot perform.
Jacky Cheung said, "I'm very sorry, but I started feeling unwell after performing in Hong Kong last week. After seeing a doctor, I confirmed that I was infected with RSV (respiratory syncytial virus), which is usually a virus that children can contract. It's probably because I'm over 60 years old, and people say that as I get older, I will gradually become a child, so I'm infected."
"I always hope for a miracle to happen, so that when I wake up, I can go to the venue for rehearsals as usual and perform at night as usual. However, the miracle has not happened." Jacky Cheung said, "My throat still hurts and I can't speak normally. Besides, there are usually symptoms such as runny nose and nasal congestion. Everyone doesn't have to worry about my health."
Jacky Cheung reluctantly announced, "It is certain that the performance will not be possible, which has disappointed the audience who bought tickets to enter the venue. We deeply apologize for the inconvenience caused to the organizers and would like to express our apologies to everyone. We hope to recover as soon as possible and return to the stage to perform for everyone. We wish everyone good health!"
The organizer of the performance also issued a statement stating that Mr. Jacky Cheung was diagnosed with a respiratory infection by a doctor and was ordered to take necessary rest. We deeply apologize for any inconvenience caused to fans who have already purchased tickets for the June 7th, 8th, and 9th performances. We will submit a ticket refund and related compensation plan at 7:30 pm on June 7th.
Previously, on March 7th, Jacky Cheung cancelled three concerts held at the Shanghai Oriental Sports Center on March 8th, 9th, and 10th due to health reasons.
According to public information, Jacky Cheung was born on July 10, 1961 in Hong Kong. He is a male Chinese pop singer, actor, and composer, and is loved by many fans.
After the recovery of the performance market last year, Jacky Cheung held numerous concerts in various places, which posed a physical challenge to him as he was over 60 years old. According to media reports, according to incomplete statistics, the "Jacky Cheung 60+Tour" has held over 100 concerts in different countries and regions since June 9, 2023, starting from Macau. On average, one concert takes less than three days.
What is respiratory syncytial virus?
Respiratory syncytial virus, also known as respiratory syncytial virus, is an RNA virus belonging to the family Pneumaviridae and the genus Orthopulmonary virus. People of all ages can be infected with RSV, but the high-risk population for RSV infection is mainly concentrated in children, the elderly, and immunocompromised populations.
At present, there are no respiratory syncytial virus vaccines and specific therapeutic drugs available on the market in China. Respiratory syncytial virus can be re infected and easily transmitted from home. In the absence of vaccines and effective drugs, measures such as strengthening personal protection should be taken to prevent infection.
Global pharmaceutical giants are all eyeing it
On May 31st local time, American vaccine company Moderna announced that its mRNA respiratory syncytial virus (RSV) vaccine (mRESVIA) has been approved for market by the US Food and Drug Administration (FDA). This is the second commercial mRNA vaccine in the world after COVID-19 vaccine, and also the first non COVID-19 mRNA vaccine in the world.
On June 3rd, the National Medical Products Administration's Drug Evaluation Center publicly disclosed that Pfizer had submitted its clinical trial application for its Respiratory Syncytic Virus (RSV) vaccine to the center and was accepted on June 1st.
On June 7th, the US Food and Drug Administration (FDA) expanded its approval of the GSK respiratory syncytial virus (RSV) vaccine to include adults aged 50 to 59 who are at a higher risk of worsening after contracting the virus.
This vaccine called Arexvy is the first FDA approved vaccine to protect this population from RSV infection. The agency initially approved the GSK vaccine in May 2023 for patients aged 60 and above who are more prone to severe cases of the virus.
According to data from the Centers for Disease Control and Prevention, RSV causes thousands of elderly hospitalizations and deaths each year. However, the virus may also cause serious diseases in adults aged 50 years and above, even younger adults, especially those with chronic basic diseases such as asthma, diabetes and congestive heart failure.
Many domestic pharmaceutical companies are also laying out RSV vaccines. According to public information, most of them are in the early stage of research and development, and are not based on mRNA technology. According to a research report by AVIC Securities, the RSV vaccine market is still in its early stages of rapid opening up. In addition to protective efficacy, broad-spectrum protection ability, sustained vaccination ability, and safety are the main differentiated competitive indicators of RSV vaccines.
The RSV vaccine (project number ADV110) of Adivixin belongs to the RSV recombinant protein subunit vaccine and is in the second phase of research. In October 2023, the company announced that the team published a research paper on phase II clinical data of ADV110 on the medical preprint platform medRxiv, showcasing the phase II clinical trial research data obtained through mid-term analysis. Safety data shows that different doses of ADV110 vaccines have good safety and tolerability. Immunogenicity data shows that ADV110 immunization can induce high levels of antibodies in the body, demonstrating good immunogenicity and dose-response relationship.
The SCB-1019 of Clover Biologics (2197. HK) is a candidate vaccine for the divalent RSV PreF trimer subunit and is currently in phase one clinical stage. In April of this year, Clover Biotech announced that the first batch of young adult groups obtained positive preliminary immunogenicity and safety data in evaluating the Phase I clinical trial of SCB-1019.
Zhifei Biotechnology, which has partnered with GlaxoSmithKline, has set out in the RSV adult vaccine field, but there is not much relevant information. The 2023 financial report shows that the vaccine is in the preclinical research stage and is expected to be declared for clinical use from 2024 to 2025.
Watson Biotechnology (300142), a leading domestic private vaccine company, has obtained an RSV vaccine pipeline through cooperation with mRNA technology company Shanghai Blue Magpie Biotechnology. The 2022 annual report of Watson Biology shows that the progressiveness of the company's mRNA vaccine technology platform has been verified in several mRNA vaccines. The company and its partners have jointly developed mRNA RSV vaccines, etc., which are currently in continuous progress. In the 2023 financial report, Watson Biotech did not mention the latest progress of RSV vaccines, but only stated that it aims to gradually achieve the launch of RSV vaccines and other products in the next 5-10 years.